Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States
AimsThis study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world settings.MethodsWe analysed 2022–2023 Adelphi HF cross-sectional surv...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633435/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222603784323072 |
|---|---|
| author | Stephen J. Greene Stephen J. Greene Catelyn R. Coyle Lucy N. Hancock Kathryn W. Tebbs Sophie G. Barlow Andra S. Stevenson Engels N. Obi |
| author_facet | Stephen J. Greene Stephen J. Greene Catelyn R. Coyle Lucy N. Hancock Kathryn W. Tebbs Sophie G. Barlow Andra S. Stevenson Engels N. Obi |
| author_sort | Stephen J. Greene |
| collection | DOAJ |
| description | AimsThis study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world settings.MethodsWe analysed 2022–2023 Adelphi HF cross-sectional survey from United States physicians and their adult patients. Patients prescribed vericiguat were compared with patients eligible for but not prescribed vericiguat. Vericiguat eligibility was defined as ≥1 prior HF hospitalization at any time, ejection fraction (EF) <45%, and no stage 5 chronic kidney disease or need for dialysis. Both cohorts were compared descriptively, and logistic regression used to identify factors associated with vericiguat non-use.ResultsOverall, 93 physicians reported data on 228 patients with HF (mean age [SD]: 66.8 years [11.8], 65.7% male, 60.1% White), with 98 patients prescribed vericiguat and 130 patients eligible but not prescribed vericiguat. Patients eligible but not prescribed vericiguat had more comorbid hypertension (62.3% vs. 45.9%), hyperlipidemia (52.3% vs. 34.7%), and lower EF (mean [SD]: 34.7% [5.8%] vs. 41.7% [9.6%]), all p < 0.05. For every 1% increase in EF above 38%, odds of being prescribed vericiguat increased by 44% (Odds Ratio [CI]: 1.44 [1.28, 1.63]; p < 0.05).ConclusionAmong patients with HF in contemporary US clinical practice, patients prescribed vericiguat have distinct demographic and clinical profiles compared to eligible patients not prescribed vericiguat. Future research should confirm these findings and explore whether subgroups of eligible patients less likely to be prescribed vericiguat may benefit from targeted implementation initiatives. |
| format | Article |
| id | doaj-art-3e7b57384a9344788bffc6cf250e4cb6 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-3e7b57384a9344788bffc6cf250e4cb62025-08-26T04:12:45ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-08-011210.3389/fcvm.2025.16334351633435Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United StatesStephen J. Greene0Stephen J. Greene1Catelyn R. Coyle2Lucy N. Hancock3Kathryn W. Tebbs4Sophie G. Barlow5Andra S. Stevenson6Engels N. Obi7Duke Clinical Research Institute, Durham, NC, United StatesDivision of Cardiology, Duke University School of Medicine, Durham, NC, United StatesValue and Implementation, Merck & Co., Inc., Rahway, NJ, United StatesAdelphi Real World, Bollington, United KingdomAdelphi Real World, Bollington, United KingdomAdelphi Real World, Bollington, United KingdomValue and Implementation, Merck & Co., Inc., Rahway, NJ, United StatesValue and Implementation, Merck & Co., Inc., Rahway, NJ, United StatesAimsThis study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world settings.MethodsWe analysed 2022–2023 Adelphi HF cross-sectional survey from United States physicians and their adult patients. Patients prescribed vericiguat were compared with patients eligible for but not prescribed vericiguat. Vericiguat eligibility was defined as ≥1 prior HF hospitalization at any time, ejection fraction (EF) <45%, and no stage 5 chronic kidney disease or need for dialysis. Both cohorts were compared descriptively, and logistic regression used to identify factors associated with vericiguat non-use.ResultsOverall, 93 physicians reported data on 228 patients with HF (mean age [SD]: 66.8 years [11.8], 65.7% male, 60.1% White), with 98 patients prescribed vericiguat and 130 patients eligible but not prescribed vericiguat. Patients eligible but not prescribed vericiguat had more comorbid hypertension (62.3% vs. 45.9%), hyperlipidemia (52.3% vs. 34.7%), and lower EF (mean [SD]: 34.7% [5.8%] vs. 41.7% [9.6%]), all p < 0.05. For every 1% increase in EF above 38%, odds of being prescribed vericiguat increased by 44% (Odds Ratio [CI]: 1.44 [1.28, 1.63]; p < 0.05).ConclusionAmong patients with HF in contemporary US clinical practice, patients prescribed vericiguat have distinct demographic and clinical profiles compared to eligible patients not prescribed vericiguat. Future research should confirm these findings and explore whether subgroups of eligible patients less likely to be prescribed vericiguat may benefit from targeted implementation initiatives.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633435/fullvericiguatheart failureeligibilityUnited Statesejection fraction |
| spellingShingle | Stephen J. Greene Stephen J. Greene Catelyn R. Coyle Lucy N. Hancock Kathryn W. Tebbs Sophie G. Barlow Andra S. Stevenson Engels N. Obi Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States Frontiers in Cardiovascular Medicine vericiguat heart failure eligibility United States ejection fraction |
| title | Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States |
| title_full | Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States |
| title_fullStr | Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States |
| title_full_unstemmed | Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States |
| title_short | Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States |
| title_sort | eligible patients with heart failure prescribed vs not prescribed vericiguat in the united states |
| topic | vericiguat heart failure eligibility United States ejection fraction |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633435/full |
| work_keys_str_mv | AT stephenjgreene eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT stephenjgreene eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT catelynrcoyle eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT lucynhancock eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT kathrynwtebbs eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT sophiegbarlow eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT andrasstevenson eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates AT engelsnobi eligiblepatientswithheartfailureprescribedvsnotprescribedvericiguatintheunitedstates |